Praxis Precision Medicines, Inc.
PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depressiā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$292.02
Price-3.74%
-$11.35
1Y
Price
Market Cap
$6.174b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-100.0%
1y CAGR+49.8%
3y CAGR+37.4%
5y CAGREarnings
-$303.268m
-65.9%
1y CAGR-23.9%
3y CAGR-25.0%
5y CAGREPS
-$13.48
-31.8%
1y CAGR+28.9%
3y CAGR+17.3%
5y CAGRBook Value
$878.136m
$937.907m
Assets$59.771m
Liabilities$110k
DebtDebt to Assets
0.0%
-
Debt to EBITDAFree Cash Flow
-$249.124m
-89.4%
1y CAGR-22.6%
3y CAGR-28.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company